Table 2.
Hazard of death: multivariable analysis
| Patient characteristics | Unadjusted HR | 95% CI | P value | Fully adjusted HR | 95% CI | P value |
| Female | 1 | 1 | ||||
| Male | 1.13 | 0.65 to 1.96 | p=0.656 | 1.17 | 0.66 to 2.10 | p=0.574 |
| PS 0 | 1 | 1 | ||||
| PS≥1 | 2.00 | 1.14 to 3.53 | p=0.016 | 2.11 | 1.12 to 3.97 | p=0.020 |
| Stage I | 1 | 1 | ||||
| Stage II | 2.07 | 0.49 to 8.79 | p=0.326 | 1.55 | 0.35 to 6.79 | p=0.563 |
| Stage III | 4.31 | 1.01 to 18.35 | p=0.050 | 3.18 | 0.72 to 14.00 | p=0.126 |
| Radiotherapy | 1 | 1 | ||||
| Chemoradiotherapy | 0.92 | 0.50 to 1.71 | p=0.793 | 0.88 | 0.45 to 1.72 | p=0.708 |
| GTV<6 cm | 1 | 1 | ||||
| GTV≥6 cm | 1.96 | 11.0 to 3.47 | p=0.021 | 1.86 | 1.03 to 3.37 | p=0.041 |
HRs by patient characteristics, treatment modality and gross tumour volume lengths.
GTV, gross tumour volume; PS, performance status.